Tissue distribution kinetics of a new nonsteroidal 5A-reductase inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1- YL]-butyric acid, in rats

Drug Metabolism and Disposition

Volumn 25, Issue 9, 1997, Pages 1051-1058

  Katashima, Masataka ^a   Yamamoto, Koujirou ^b   Haraguchi, Kaori ^b   Tokuma, Yoji ^b   Hata, Takehisa ^b   Sawada, Yasufumi ^b   Iga, Tatsuji ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ENZYME INHIBITORS; HALF-LIFE; INDOLES; INJECTIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; PHENYLBUTYRATES; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH; TESTOSTERONE 5-ALPHA-REDUCTASE;

ANIMALIA;

EID: 0030876402     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. K. M. Anderson and S. Liao: Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219, 277-279 (1968).
2. N. Bruchovsky and J. D. Wilson: The conversion of testosterone to 5′α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 243, 2012-2021 (1968).
3. S. Bruchovsky and J. D. Wilson: The intranuclear binding of testosterone und 5α-androstan-17β-ol-3-one by rat prostate. J. Biol. Chem. 243, 5953-5960 (1968).
4. G. L. Hammond: Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J. Endocrinol. 78, 7-19 (1978).
5. A. A. Sandberg: Endocrine control and physiology of the prostate. Prostate 1, 169-184 (1980).
6. R. E. Gloyna, P. K. Siiteri, and D. J. Wilson: Dihydrotestosterone in prostatic hypertrophy. I. The formation und content of dihydrotestosterone in the hypertrophic prostate of man. J. Clin. Invest. 49, 1737-1745 (1970).
7. R. E. Gloyna, P. K. Siiteri, and D. J. Wilson: Dihydrotestosterone in prostatic by pertrophy. II. The formation and content of dihydrotestosterone on prostatic growth in the dog. J. Clin. Invest. 49, 1746-1753 (1970).
8. R. W. Hudson, P. M. Moffitt, and W. A. Owens: Studies of the nuclear Sα-reductase of human prostatic tissue: comparison of enzyme activities in hyperplastic, malignant and normal tissue. Can. J. Biochem. Cell Biol. 61, 750-755 (1982).
9. D. H. Peters and E. M. Sorkin: Finasteride - a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46, 177-208 (1993).
10. R. S. Rittmaster: Drug therapy- finasteride. N. Engl. J. Med. 330, 120-125 (1994).
11. J. Hirosumi, O. Nakayama, T. Fagan, K. Sawada, N. Chida, M. Inami, S. Takahashi, H. Kojo, Y. Notsu, and M. Okuhara: FK143. a novel nonsteroidal inhibitor of steroid 5α-reductase (1) in vitro effects of human and animal prostatic enzymes. J. Steroid. Biochem. Mol. Biol. 52, 357-363 (1995).
12. + -independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Phvsiol. 264, G36-G44 (1993).
13. T. Niwa, Y. Tokuma, and H. Noguchi: Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog. Res. Commun. Chem. Pathol. Pharmacol. 55. 75-88 (1987).
14. K. Yamamoto, Y. Sawada, and T. Iga: Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats. J. Pharmacokinet. Biopharm. 24, 327-348 (1996).
15. A. Bernareggi and M. Rowland: Physiologic modeling of cyclosporin kinetics in rat and man. J. Phannacokinet. Biopharm. 19, 21-50 ( 19911).
16. J.-E. Damber and P.O. Jamson: Methodological aspects of testicular blood flow measurement in rats. Ada Physinl. Scand. 101, 278-285 (1977).
17. G. M. H. Waites and B. P. Setchell: Changes in blood flow and vascular permeability of the testis. epididymis and accessory reproductive organs of the rat after the administration of cadmium chloride. J. Endocrinol. 34, 329-342 (1966).
18. A. Tsuji, T. Yoshikawa, K. Nishide, H. Minami, M. Kimura, E. Nakashima, T. Terasaki, E. Miyamoto, C. H. Nightingale, and T. Yamana: Physiologically based pharmacokinetic model for β-lactam antibiotics. I. Tissue distribution and elimination in rats. J. Pharm. Sci. 72, 1239-1252 (1983).
19. J. M. Gallo, C.T. Hung, P. K. Gupta, and D. G. Perrier: Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat. J. Pharmacokinet. Binpharm. 17, 305-326 (1989).
20. K. Okumura, I. P. Lee, and R. L. Dixon: Permeability of selected drugs and chemicals across the blood-testis barrier of the rat. J. Pharmacol. Exp. Ther. 194, 89-95 (1975).
21. E. M. Renkin: The Microcirculatory Society Eugene M. Landis Award Lecture. Microvasc. Res. 15, 123-135 (1978).
22. T. Terasaki, T. Iga, Y. Sugiyama, and M. Hanano: Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J. Pharm. Pharmacol. 34. 597-600 (1982).
23. T. Terasaki, T. Iga, Y. Sugiyama, and M. Hanano: Interaction of doxorubicin with nuclei isolated from rat liver and kidney. J. Pharm. Sci. 73, 524-528 (1984).
24. T. Terasaki, T. Iga, Y. Sugiyama, and M. Hanano: Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-plasma partition coefficients in rats. rabbits and guinea pigs. J. Pharm. Sci. 73, 1359-1363 (1984).
25. N. Yata, T. Toyoda, T. Murakami, A. Nishiura, and Y. Higashi: Phosphatidylserine as determinant for the tissue distribution of weakly basic drugs in rats. Pharm. Res. 7, 1019-1025 (1990).
26. H. Harashima. Y Sugiyama, T. Iga, and M. Hanano: Nonlinear tissue distribution of ouabain in rabbits. Drug Metab. Dispos. 16, 645-649 (1988).
27. + - ATPase in the tissue distribution of ouabain in guinea pigs. Pharm. Res. 9, 474-479 (1992).
28. H. H. W. Thijssen and L. G. M Baars: Microsomal warfarin binding and vitamin K 2.3-epoxide reductase. Biochem. Pharmacol. 38, 1115-1120 (1989).
29. H. H. W. Thijssen and L. G. M. Baars: Tissue distribution of selective wartarin binding sites in the rat. Biochem. Pharmacol. 42, 2181-2186 (1991).
30. H. H. W. Thijssen and Y. P. G. Janssen: Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect. J. Pharmacol. Exp. Ther. 270, 554-558 (1994).
31. G. Verhoeven, G. Lamberigts, and P. De Moor: Nucleus-associated steroid 5α-reductase activity and androgen responsiveness. A study in various organs and brain regions of rats. J. Steroid Biochem. 5, 93-100 (1974).
32. A. E. Thigpen, R. I. Silver, J. M. Guileyardo, M. LinetteCasey, J. D. McConnell, and D. W. Russell: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest. 92, 903-910 (1993).
33. K. Normington and D. W. Russell: Tissue distribution and kinetic characteristic of rat steroid 5α-reductase isozyme. J. Biol. Chem. 267, 19548-19554 (1992).